Equities

InMed Pharmaceuticals Inc

InMed Pharmaceuticals Inc

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)0.2649
  • Today's Change-0.008 / -3.00%
  • Shares traded381.43k
  • 1 Year change-67.43%
  • Beta0.7490
Data delayed at least 15 minutes, as of Sep 20 2024 21:00 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Forecasts data is unavailable for this security.

Share price forecast

The one analyst offering a 12 month price target expects InMed Pharmaceuticals Inc share price to rise to 20.00 in the next year from the last price of 0.2649.
High7,450.0%20.00
Med7,450.0%20.00
Low7,450.0%20.00

Earnings history & estimates in USD

Annual earnings information is not available for InMed Pharmaceuticals Inc.
Average growth rate+12.71%
More ▼

Revenue history & estimates in USD

InMed Pharmaceuticals Inc. had 3rd quarter 2024 revenues of 1.17m. This missed the 1.49m estimate of the one analyst following the company. This was 265.42% above the prior year's 3rd quarter results.
Average growth rate+23.67%
InMed Pharmaceuticals Inc. had revenues for the full year 2023 of 4.14m. This was 279.80% above the prior year's results.
Average growth rate+279.80%
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.